Relief Therapeutics Holding SA (SWX:RLF)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
2.210
+0.170 (8.33%)
Apr 3, 2025, 2:35 PM CET
70.00%
Market Cap 25.58M
Revenue (ttm) 8.60M
Net Income (ttm) -46.24M
Shares Out 12.54M
EPS (ttm) -3.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,990
Average Volume 23,907
Open 2.040
Previous Close 2.040
Day's Range 2.040 - 2.330
52-Week Range 1.055 - 7.600
Beta -15.30
RSI 24.78
Earnings Date Apr 1, 2025

About SWX:RLF

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 49
Stock Exchange SIX Swiss Exchange
Ticker Symbol RLF
Full Company Profile

Financial Performance

In 2023, SWX:RLF's revenue was 6.03 million, a decrease of -0.79% compared to the previous year's 6.08 million. Losses were -98.18 million, 93.3% more than in 2022.

Financial Statements

News

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov...

4 weeks ago - Accesswire

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTC...

7 weeks ago - Accesswire

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Sale of GOLIKE® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELI...

2 months ago - Accesswire

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un...

2 months ago - Accesswire

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin...

3 months ago - Accesswire

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE / De...

3 months ago - Accesswire

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF)...

3 months ago - Accesswire

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

5 months ago - Accesswire

Relief Therapeutics signs letter of intent with Renexxion for reverse merger

Relief Therapeutics signs non-binding letter of intent with Renexxion for a reverse merger, strengthening their competitive position in biotech industry.

5 months ago - Seeking Alpha

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i...

5 months ago - Accesswire

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

5 months ago - Accesswire

Relief gains as experimental therapy performs on par with BioMarin’s Kuvan

Relief Therapeutics (RLFTF) stock gains on positive data for RLF-OD032, an experimetal therapy targeted at BioMarin's (BMRN) phenylketonuria drug Kuvan. Read more here.

6 months ago - Seeking Alpha

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin...

7 months ago - Accesswire

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

7 months ago - Accesswire

Relief Therapeutics reports 1H results

7 months ago - Seeking Alpha

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined ope...

7 months ago - Accesswire

Relief Therapeutics Secures up to $11 Million from Royalty Sales

Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:...

8 months ago - Accesswire

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to de...

10 months ago - Accesswire

Relief Therapeutics Announces Executive Changes

GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to del...

10 months ago - Accesswire

Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives

GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innova...

11 months ago - Accesswire

Relief Therapeutics has Published its Annual Report

GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatmen...

1 year ago - Accesswire

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the C...

1 year ago - Accesswire